Theravance Biopharma (NASDAQ:TBPH) had its target price hoisted by equities researchers at Leerink Swann from $45.00 to $48.00 in a research report issued on Thursday. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Swann’s target price indicates a potential upside of 72.17% from the stock’s current price.

Other research analysts have also issued reports about the company. BidaskClub lowered Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. ValuEngine downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $55.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, November 7th. Robert W. Baird reaffirmed a “sell” rating and set a $22.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $42.00.

Theravance Biopharma (TBPH) traded down $0.13 during trading hours on Thursday, hitting $27.88. The stock had a trading volume of 39,863 shares, compared to its average volume of 230,718. Theravance Biopharma has a 1-year low of $22.90 and a 1-year high of $43.44. The company has a debt-to-equity ratio of 1.21, a current ratio of 7.53 and a quick ratio of 7.21. The company has a market cap of $1,322.29, a price-to-earnings ratio of -5.39 and a beta of 1.88.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.05). Theravance Biopharma had a negative return on equity of 99.43% and a negative net margin of 1,604.87%. sell-side analysts predict that Theravance Biopharma will post -4.84 earnings per share for the current year.

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Theravance Biopharma by 3.6% during the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock worth $144,972,000 after buying an additional 126,393 shares during the period. Alps Advisors Inc. raised its stake in shares of Theravance Biopharma by 10.3% in the 3rd quarter. Alps Advisors Inc. now owns 53,013 shares of the biopharmaceutical company’s stock valued at $1,815,000 after purchasing an additional 4,944 shares during the period. New York State Common Retirement Fund raised its stake in shares of Theravance Biopharma by 9.2% in the 2nd quarter. New York State Common Retirement Fund now owns 46,300 shares of the biopharmaceutical company’s stock valued at $1,845,000 after purchasing an additional 3,899 shares during the period. Northern Trust Corp raised its stake in shares of Theravance Biopharma by 6.1% in the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock valued at $21,117,000 after purchasing an additional 30,611 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Theravance Biopharma by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after purchasing an additional 116,981 shares during the period. 86.04% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Theravance Biopharma (TBPH) PT Raised to $48.00” was posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/02/08/theravance-biopharma-tbph-pt-raised-to-48-00.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.